195 related articles for article (PubMed ID: 32423950)
1.
Cotroneo N; Rubio A; Critchley IA; Pillar C; Pucci MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423950
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections.
Sun Z; Su L; Cotroneo N; Critchley I; Pucci M; Jain A; Palzkill T
Antimicrob Agents Chemother; 2022 May; 66(5):e0239621. PubMed ID: 35491852
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.
Eckburg PB; Jain A; Walpole S; Moore G; Utley L; Manyak E; Dane A; Melnick D
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262768
[TBL] [Abstract][Full Text] [Related]
4. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Eckburg PB; Muir L; Critchley IA; Walpole S; Kwak H; Phelan AM; Moore G; Jain A; Keutzer T; Dane A; Melnick D; Talley AK
N Engl J Med; 2022 Apr; 386(14):1327-1338. PubMed ID: 35388666
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections.
McEntee L; Johnson A; Farrington N; Unsworth J; Dane A; Jain A; Cotroneo N; Critchley I; Melnick D; Parr T; Ambrose PG; Das S; Hope W
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109982
[TBL] [Abstract][Full Text] [Related]
6. Contemporary Evaluation of Tebipenem
Mendes RE; Arends SJR; Streit JM; Critchley I; Cotroneo N; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0205722. PubMed ID: 36625644
[TBL] [Abstract][Full Text] [Related]
7. Tebipenem, the first oral carbapenem antibiotic.
Jain A; Utley L; Parr TR; Zabawa T; Pucci MJ
Expert Rev Anti Infect Ther; 2018 Jul; 16(7):513-522. PubMed ID: 30014729
[TBL] [Abstract][Full Text] [Related]
8. Tebipenem pivoxil hydrobromide-No PICC, no problem!
Sodhi V; Kronsberg KA; Clark M; Cho JC
Pharmacotherapy; 2021 Sep; 41(9):748-761. PubMed ID: 34370326
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide.
Ganesan H; Gupta VK; Safir MC; Bhavnani SM; Talley AK; Melnick D; Rubino CM
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0145122. PubMed ID: 37191505
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
11. Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
Rodvold KA; Gotfried MH; Gupta V; Ek A; Srivastava P; Talley A; Bruss J
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0059022. PubMed ID: 35762796
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms.
Arends SJR; Rhomberg PR; Cotroneo N; Rubio A; Flamm RK; Mendes RE
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936096
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems.
Rubio A; Pucci MJ; Jain A
ACS Infect Dis; 2018 Oct; 4(10):1436-1438. PubMed ID: 30118209
[TBL] [Abstract][Full Text] [Related]
14.
Clayton NP; Jain A; Halasohoris SA; Pysz LM; Lembirik S; Zumbrun SD; Kane CD; Hackett MJ; Pfefferle D; Smiley MA; Anderson MS; Heine H; Meister GT; Pucci MJ
Antimicrob Agents Chemother; 2021 May; 65(5):. PubMed ID: 33593844
[No Abstract] [Full Text] [Related]
15. Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial.
Sewunet T; Razavi M; Rosenborg S; Camporeale A; Nowak M; Melnick D; Gasink LB; Eckburg PB; Critchley IA; Nord CE; Giske CG
Lancet Microbe; 2024 Apr; 5(4):e355-e365. PubMed ID: 38432233
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
[TBL] [Abstract][Full Text] [Related]
17.
Lacasse E; Brouillette E; Larose A; Parr TR; Rubio A; Malouin F
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718255
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber
VanScoy BD; Jones S; Conde H; Friedrich LV; Cotroneo N; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2023 Mar; 67(3):e0090822. PubMed ID: 36757190
[TBL] [Abstract][Full Text] [Related]
19. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
20.
Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
